| Cat.No. | Name | Information |
|---|---|---|
| M1721 | AZD4547 | AZD4547 is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. |
| M1840 | BGJ398 (Infigratinib) | BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
| M9715 | Erdafitinib | Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity. |
| M10048 | PF-05231023 | PF-05231023 is an FGF21-receptor agonist, it is also a potential treatment for T2DM. |
| M1875 | PD173074 | PD173074 is a selective FGFR1 and FGFR3 inhibitor with IC50 values of 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively. |
| M45218 | ABSK061 | ABSK061 is an orally active, selective, small molecule FGFR2/3 inhibitor for studies related to solid tumors. |
| M45217 | ABSK121 | ABSK121 is an orally active, highly selective small molecule FGFR inhibitor. |
| M45216 | ABSK012 | ABSK012 is a highly selective FGFR4 inhibitor with antitumor activity for studies related to soft tissue sarcoma (STS). |
| M43509 | S6K2-IN-1 | S6K2-IN-1 is a S6K2 inhibitor (IC50: 22 nM). |
| M43508 | FGFR4-IN-14 | FGFR4-IN-14 is a FGFR4 inhibitor (IC50: 2.4 nM. |
| M43507 | FGFR1 inhibitor-10 | FGFR1 inhibitor-10 is an FGFR1 inhibitor (IC50: 28 nM). |
| M43506 | FGFR1 inhibitor-8 | FGFR1 inhibitor-8 is a FGFR1 inhibitor (IC50s: 0.5 nM). |
| M43505 | Formononetin-d3-1 | Formononetin-d3-1 is the deuterium-labeled Formononetin. |
| M43504 | FGFR1 inhibitor-9 | FGFR1 inhibitor-9 is an FGFR1 inhibitor (IC50s: 0.85 nM). |
| M43503 | FGFR4-IN-16 | FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4 for cancer research. |
| M43502 | FGFR1 inhibitor 7 | FGFR1 inhibitor 7 is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. |
| M43501 | Resigratinib | Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect. |
| M43500 | LC-MB12 | LC-MB12 is an orally active PROTAC compound targets FGFR2 degradation with a DC50 of 11.8 nM. |
| M43499 | Irpagratinib | Irpagratinib (ABSK011) is a potentially best-in-class, orally active fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor targeting FGFR4 (IC50<10 nM). |
| M40986 | NGM-313 | NGM-313 is a β-Klotho/FGFR1c-targeted monoclonal antibody for studies related to non-alcoholic steatohepatitis (NASH). |
| M40984 | BOS-580 | BOS-580 is an FGF21 analog and modulator for studies related to non-alcoholic steatohepatitis (NASH). |
| M40899 | LOXO-435 | LOXO-435 is a highly selective fibroblast growth factor receptor-3 (FGFR3) antagonist that can be used in a variety of tumor-related studies. |
| M30269 | Surfen dihydrochloride | Surfen dihydrochloride is a potent HS (heparan sulfate) antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins. Surfen affects sulfation of heparin and inhibits degradation by heparin lyases. Surfen inhibits FGF2 binding and signaling. Surfen inhibits cell attachment, and virus infection. |
| M28979 | E7090 succinate | E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively. |
| M28863 | PD-089828 | PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
